HS-10516 not checked

Hansoh

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
2 active
3 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Advanced Clear Cell Renal Cell Carcinoma, Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma
Main trialPhase 1/2
“This is a multicenter, open-label, Phase Ib/II clinical study evaluating the safety, efficacy, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) profiles of HS-10516 in combination with lenvatinib in patients with advanced clear cell renal cell carcinoma (ccRCC) who have progressed after receiving at least one prior line of systemic therapy. The study comprises two distinct phases: a dose exploration phase and a proof-of-concept phase.”In the company’s words, NCT07097935 on ClinicalTrials.gov

Other drugs for Advanced Clear Cell Renal Cell Carcinoma

All 16 drugs for Advanced Clear Cell Renal Cell Carcinoma

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting 10 Jul 2027 Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma
Phase 1Recruiting 31 Jul 2026 A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors
Phase 1Unknown 25 Sep 2024 A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow HS-10516

Following is part of Solo: you see every change to HS-10516 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in